


Day Break

Wednesday, March 5, 2025









Oil & Gas Marketing Companies

Feb-25: Volumes Inch up by +2%y/y to 1.14 mntons; Down by 18%m/m

- Industry volumes for oil marketing companies for the month of Feb-25 remained flat at 1.14mn ton bringing industry volumes for 8MFY25 to 10.55mn ton up by +4%Y/y. Furnace Oil (FO) / Motor Spirit (MS) sales were up by +7%/+2%y/y during Feb-25 while High Speed Diesel (HSD) sales were down by 4%y/y. On a monthly basis, industry volumes plumetted by 18%m/m to 1.14mn ton during Feb-25 on the back of 29%/11%/9%m/m decline in HSD/MS/FO sales.
- During the 8MFY25, HSD/MS sales increased by +9/+4%y/y while FO sales declined by 42%y/y. Company wise APL/PSO witnessed 11%/6%y/y decline in total sales while HASCOL/SHEL reported +34%/+4%y/y growth during 8MFY25. Market share for PSO and APL dropped by 4.8% and 1.5% to 45% and 9% respectively during 8MFY25 against 50% and 10% in the same period last year, while SHEL and HASCOL reported 0.1% and 0.7% growth in market share during 8MFY25 respectively.
- Cut in interest rate by SBP is likely to give slight push to passenger car sales. However, rise in HEV sales and potential launch of EV cars are also likely to restrict demand growth of petrol engines going forward. Potential hike in OMC margins are likely to support earnings amid depressed demand. Continued improvement in cash collection is likely to keep cash flows strong for PSO going forward and may unlock valuations.

Feb-25: POL sales inched up by 2%y/y to 1.14mn ton

Industry volumes for oil marketing companies for the month of Feb-25 remained flat at 1.14mn ton bringing industry volumes for 8MFY25 to 10.55mn ton up by +4%Y/y. Furnace Oil (FO) / Motor Spirit (MS) sales were up by +7%/+2%y/y during Feb-25 while High Speed Diesel (HSD) sales were down by 4%y/y. On a monthly basis, industry volumes plummeted by 18%m/m to 1.14mn ton during Feb-25 on the back of 29%/11%/9%m/m decline in HSD/MS/FO sales.

During the 8MFY25, HSD/MS sales increased by +9/+4%y/y while FO sales declined by 42%y/y. Company wise APL/PSO witnessed 11%/6%y/y decline in total sales while HASCOL/SHEL reported +34%/+4%y/y growth during 8MFY25. Market share for PSO and APL dropped by 4.8% and 1.5% to 45% and 9% respectively during 8MFY25 against 50% and 10% in the same period last year, while SHEL and HASCOL reported 0.1% and 0.7% growth in market share during 8MFY25 respectively.

Abdullah Farhan

Abdullah.farhan@igi.com.pk



MS

MS sales inched up by +2%y/y to 0.56mn ton during Feb-25 while on sequential basis volumes dropped by 11%m/m. PSO, SHEL, APL and HASCOL recorded 14%y/y, 14%y/y, 13%y/y and 8%y/y decline in volumes respectively during Feb-25. For 8MFY25, MS volumes increased by +4%y/y to 4.93mn ton. During 8MFY25, HASCOL and SHEL posted +17%y/y and +1%y/y growth in volumes respectively, whereas, PSO and APL recorded 6%y/y and 4%y/y drop in total MS sales. PSO, APL and SHEL's market share dropped to 41.2%, 8.4% and 9.4% during 8MFY25 from 45.9%, 9.2% and 9.7% respectively in the same period last year. HASCOL's market share increased to 4.0% during 8MFY25 from 3.6% in the similar period last year.

HSD

HSD sales declined up by 4%y/y to 0.43mn ton in Feb-25 and on monthly basis volumes nosedived by 29%m/m. APL, PSO, HASCOL and SHEL reported 38%y/y, 31%y/y, 28%y/y and 27%y/y drop in sales respectively during Feb-25. This brings total 8MFY25 sales at 4.49mn ton up by +9%y/y. For 8MFY25, HASCOL, APL and SHEL posted +58%y/y, +3%y/y and +1%y/y incline in sales with market share for HASCOL increasing to 2.9%. PSO reported 7%y/y decline in total HSD sales during 8MFY25. Market share for PSO, APL and SHEL dropped by 8.0%, 0.5% and 0.5% respectively.

FO

FO volumes increased by +7%y/y during Feb-25 to 0.05mn ton likely attributable to slightly higher demand from IPPs compared to last year. Volumes are down by 9%m/m during Feb-25. Total FO volumes are down by 42%y/y during 8MFY25 to 0.46mn ton. For 8MFY25, PSO and APL reported 48%y/y and 61%y/y decline in sales with PSO's market share declining to 19.5% compared to 21.5% in 8MFY24, whereas, APL's market share dropped to 17.1% from 25.2% in the same period last year.

Outlook

Cut in interest rate by SBP is likely to give slight push to passenger car sales. However, rise in HEV sales and potential launch of EV cars are also likely to restrict demand growth of petrol engines going forward. Potential hike in OMC margins are likely to support earnings amid depressed demand. Continued improvement in cash collection is likely to keep cash flows strong for PSO going forward and may unlock valuations.



HSD 428.5 599.8 -29% 446.2 -4% 1,028.3 959.2 7% 4,490.9 4,117.8 9% 1.028.3 959.2 7% 4,490.9 4,117.8 9% 1.028.3 959.2 7% 4,490.9 4,117.8 9% 1.028.5 99.4 102.6 -3% 75.9 31% 202.0 146.5 38% 671.3 795.0 -42% 1.028.1 1.												
MS 555.6 623.1 -11% 544.0 2% 1,178.7 1,158.9 2% 4,929.1 4,726.7 4% 15D 428.5 599.8 -29% 446.2 -4% 1,028.3 959.2 7% 4,490.9 4,117.8 9% 100.6 52.9 58.1 -9% 49.6 7% 111.1 233.5 -52% 458.2 795.0 -42% 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% 10.1 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,138.2 1	Exhibit: O	MC's Mon	thly Sale	s Volun	ne (Feb-2	5)						
MS 555.6 623.1 -11% 544.0 2% 1,178.7 1,158.9 2% 4,929.1 4,726.7 4% 15D 428.5 599.8 -29% 446.2 -4% 1,028.3 959.2 7% 4,490.9 4,117.8 9% 100.6 52.9 58.1 -9% 49.6 7% 111.1 233.5 -52% 458.2 795.0 -42% 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% 10.1 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,136.4 1,138.2 1												
MS 555.6 623.1 -11% 544.0 2% 1,178.7 1,158.9 2% 4,929.1 4,726.7 4% HSD 428.5 599.8 -29% 446.2 -4% 1,028.3 959.2 7% 4,490.9 4,117.8 9% 52.9 58.1 -9% 49.6 7% 111.1 233.5 -52% 458.2 795.0 -42% 676.0 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% PSO 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% PSO 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% PSO 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% PSO 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% PSO 10.1 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% PSO 10.1 1,136.4 1,383.7 -18% 1,115.8 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2		Feb-25	Jan-25	MoM	Feb-24	YoY	2MCY25	2MCY24	YoY	8MFY25	8MFY24	YoY
HSD 428.5 599.8 -29% 446.2 -4% 1,028.3 959.2 7% 4,490.9 4,117.8 9% 1.00 52.9 58.1 -9% 49.6 7% 111.1 233.5 -52% 458.2 795.0 -42% 1.00 11.36.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% 1.00 1.36.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.0												
FOO 52.9 58.1 -9% 49.6 7% 111.1 233.5 -52% 458.2 795.0 -42% Others 99.4 102.6 -3% 75.9 31% 202.0 146.5 38% 671.3 543.4 24% Intent 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% PSO	MS	555.6			544.0	2%					-	
Others 99.4 102.6 -3% 75.9 31% 202.0 146.5 38% 671.3 543.4 24% Fotal 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% PSO MS 214.6 249.4 -14% 247.7 -13% 464.0 527.6 -12% 2,029.5 2,169.2 -6% HSD 178.2 259.8 -31% 234.2 -24% 438.0 507.7 -14% 2,029.5 2,169.2 -6% HSD 178.2 259.8 -31% 234.2 -24% 438.0 507.7 -14% 2,097.6 2,254.0 -7% Others 73.3 78.1 -6% 68.3 7% 151.4 131.4 15% 535.2 481.8 11% Ottal 469.6 592.0 -21% 566.7 -17% 1,061.6 1,224.4 -13% 4751.4	HSD											
Fotal 1,136.4 1,383.7 -18% 1,115.8 2% 2,520.1 2,498.1 1% 10,549.4 10,183.0 4% PSO MIS 214.6 249.4 -14% 247.7 -13% 464.0 527.6 -12% 2,029.5 2,169.2 -6% HSD 178.2 259.8 -31% 234.2 -24% 438.0 507.7 -14% 2,097.6 2,254.0 -7% FO 3.5 4.8 -27% 16.5 -79% 83.3 57.7 -86% 89.1 171.3 -48% Others 73.3 78.1 -6% 68.3 7.7% 151.4 131.4 15% 535.2 481.8 11% Others 73.3 78.1 -6% 68.3 -17% 1,061.6 1,224.4 -13% 4,751.4 5,076.3 -6% APL 44 49.8 3.2 -12.4 10.9 112.0 -10% 414.7 433.0 -4% <td>FO</td> <td></td>	FO											
MS 214.6 249.4 -14% 247.7 -13% 464.0 527.6 -12% 2,029.5 2,169.2 -6% -15D 178.2 259.8 -31% 234.2 -24% 438.0 507.7 -14% 2,097.6 2,254.0 -7% -76 -70 3.5 4.8 -27% 16.5 -79% 8.3 57.7 -86% 89.1 171.3 -48% -78 -78 -78 -78 -78 -78 -78 -78 -78 -78	Others	99.4	102.6	-3%	75.9	31%	202.0	146.5	38%	671.3	543.4	24%
MS	Total	1,136.4	1,383.7	-18%	1,115.8	2%	2,520.1	2,498.1	1%	10,549.4	10,183.0	4%
HSD 178.2 259.8 -31% 234.2 -24% 438.0 507.7 -14% 2,097.6 2,254.0 -7% FO 3.5 4.8 -27% 16.5 -79% 8.3 57.7 -86% 89.1 171.3 -48% Others 73.3 78.1 -6% 68.3 7% 151.4 131.4 15% 535.2 481.8 11% Fotal 469.6 592.0 -21% 566.7 -17% 1,061.6 1,224.4 -13% 4,751.4 5,076.3 -6% APL WIS 47.0 53.8 -13% 54.6 -14% 100.9 112.0 -10% 414.7 433.0 -4% HSD 38.2 61.4 -38% 43.5 -12% 99.7 89.9 11% 398.5 386.0 3% FO 10.8 10.8 0% 12.1 -11% 21.6 58.3 -63% 78.3 200.7 -61% Others 5.8 5.6 4% 2.7 115% 11.4 5.8 97% 37.2 25.0 49% Fotal 101.9 131.6 -23% 112.9 -10% 233.5 266.0 -12% 928.7 1,044.7 -11% HASCOL WIS 23.9 25.9 -8% 16.7 43% 49.8 32.1 55% 199.4 170.3 17% HSD 16.1 22.3 -28% 10.1 60% 38.4 17.7 118% 129.6 82.3 58% FO 1-2 0% 2.6 2.5 5% 0.1 2815% 5.1 0.1 5590% 9.7 0.4 2476% Fotal 42.6 50.7 -16% 26.8 59% 93.3 49.8 87% 338.8 252.9 34% FINEL SHELL S	PSO											
FOO 3.5 4.8 -27% 16.5 -79% 8.3 57.7 -86% 89.1 171.3 -48% Others 73.3 78.1 -6% 68.3 7% 151.4 131.4 15% 535.2 481.8 11% Fotal 469.6 592.0 -21% 566.7 -17% 1,061.6 1,224.4 -13% 4,751.4 5,076.3 -6% APL WISTON SAPE W	MS	214.6	249.4	-14%	247.7	-13%	464.0	527.6	-12%	2,029.5	2,169.2	-6%
Others 73.3 78.1 -6% 68.3 7% 151.4 131.4 15% 535.2 481.8 11% Total 469.6 592.0 -21% 566.7 -17% 1,061.6 1,224.4 -13% 4,751.4 5,076.3 -6% APL MS 47.0 53.8 -13% 54.6 -14% 100.9 112.0 -10% 414.7 433.0 -4% HSD 38.2 61.4 -38% 43.5 -12% 99.7 89.9 11% 398.5 386.0 3% FO 10.8 10.8 0% 12.1 -11% 21.6 58.3 -63% 78.3 200.7 -61% Others 5.8 5.6 4% 2.7 115% 11.4 5.8 97% 37.2 25.0 49% Others 5.8 5.6 4% 2.7 115% 11.4 5.8 97% 37.2 25.0 49% HA	HSD	178.2	259.8	-31%	234.2	-24%	438.0	507.7	-14%	2,097.6	2,254.0	-7%
Total 469.6 592.0 -21% 566.7 -17% 1,061.6 1,224.4 -13% 4,751.4 5,076.3 -6% APL MS 47.0 53.8 -13% 54.6 -14% 100.9 112.0 -10% 414.7 433.0 -4% HSD 38.2 61.4 -38% 43.5 -12% 99.7 89.9 11% 398.5 386.0 3% FO 10.8 10.8 0% 12.1 -11% 21.6 58.3 -63% 78.3 200.7 -61% Others 5.8 5.6 4% 2.7 115% 11.4 5.8 97% 37.2 25.0 49% Hotal 101.9 131.6 -23% 112.9 -10% 233.5 266.0 -12% 928.7 1,044.7 -11% HASCOL MS 23.9 25.9 -8% 16.7 43% 49.8 32.1 55% 199.4 170.3 17% <td>FO</td> <td>3.5</td> <td>4.8</td> <td>-27%</td> <td>16.5</td> <td>-79%</td> <td>8.3</td> <td>57.7</td> <td>-86%</td> <td>89.1</td> <td>171.3</td> <td>-48%</td>	FO	3.5	4.8	-27%	16.5	-79%	8.3	57.7	-86%	89.1	171.3	-48%
APL MS 47.0 53.8 -13% 54.6 -14% 100.9 112.0 -10% 414.7 433.0 -4% HSD 38.2 61.4 -38% 43.5 -12% 99.7 89.9 11% 398.5 386.0 3% 60 10.8 10.8 0% 12.1 -11% 21.6 58.3 -63% 78.3 200.7 -61% Others 5.8 5.6 4% 2.7 115% 11.4 5.8 97% 37.2 25.0 49% Total 101.9 131.6 -23% 112.9 -10% 233.5 266.0 -12% 928.7 1,044.7 -11% HASCOL MS 23.9 25.9 -8% 16.7 43% 49.8 32.1 55% 199.4 170.3 17% HSD 16.1 22.3 -28% 10.1 60% 38.4 17.7 118% 129.6 82.3 58% 60 0 - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Others	73.3	78.1	-6%	68.3	7%	151.4	131.4	15%	535.2	481.8	11%
MS 47.0 53.8 -13% 54.6 -14% 100.9 112.0 -10% 414.7 433.0 -4% HSD 38.2 61.4 -38% 43.5 -12% 99.7 89.9 11% 398.5 386.0 3% FO 10.8 10.8 0% 12.1 -11% 21.6 58.3 -63% 78.3 200.7 -61% Others 5.8 5.6 4% 2.7 115% 11.4 5.8 97% 37.2 25.0 49% Fotal 101.9 131.6 -23% 112.9 -10% 233.5 266.0 -12% 928.7 1,044.7 -11% HASCOL WIS 23.9 25.9 -8% 16.7 43% 49.8 32.1 55% 199.4 170.3 17% HSD 16.1 22.3 -28% 10.1 60% 38.4 17.7 118% 129.6 82.3 58% FO - 0 - 0 0%	Total	469.6	592.0	-21%	566.7	-17%	1,061.6	1,224.4	-13%	4,751.4	5,076.3	-6%
HSD 38.2 61.4 -38% 43.5 -12% 99.7 89.9 11% 398.5 386.0 3% FO 10.8 10.8 0% 12.1 -11% 21.6 58.3 -63% 78.3 200.7 -61% Others 5.8 5.6 4% 2.7 115% 11.4 5.8 97% 37.2 25.0 49% Fotal 101.9 131.6 -23% 112.9 -10% 233.5 266.0 -12% 928.7 1,044.7 -11% HASCOL WIS 23.9 25.9 -8% 16.7 43% 49.8 32.1 55% 199.4 170.3 17% HSD 16.1 22.3 -28% 10.1 60% 38.4 17.7 118% 129.6 82.3 58% FO 0% - 0% - 0% - 0% - 0% - 0% - 0% -	APL											
FO 10.8 10.8 0% 12.1 -11% 21.6 58.3 -63% 78.3 200.7 -61% Others 5.8 5.6 4% 2.7 115% 11.4 5.8 97% 37.2 25.0 49% Fotal 101.9 131.6 -23% 112.9 -10% 233.5 266.0 -12% 928.7 1,044.7 -11% HASCOL MS 23.9 25.9 -8% 16.7 43% 49.8 32.1 55% 199.4 170.3 17% HSD 16.1 22.3 -28% 10.1 60% 38.4 17.7 118% 129.6 82.3 58% FO - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0	MS	47.0	53.8	-13%	54.6	-14%	100.9	112.0	-10%	414.7	433.0	-4%
Others 5.8 5.6 4% 2.7 115% 11.4 5.8 97% 37.2 25.0 49% Fotal 101.9 131.6 -23% 112.9 -10% 233.5 266.0 -12% 928.7 1,044.7 -11% HASCOL MS 23.9 25.9 -8% 16.7 43% 49.8 32.1 55% 199.4 170.3 17% HSD 16.1 22.3 -28% 10.1 60% 38.4 17.7 118% 129.6 82.3 58% FO - - 0% - - 0% - - 0% Others 2.6 2.5 5% 0.1 2815% 5.1 0.1 5590% 9.7 0.4 2476% Total 42.6 50.7 -16% 26.8 59% 93.3 49.8 87% 338.8 252.9 34% SHEL <t< td=""><td>HSD</td><td>38.2</td><td>61.4</td><td>-38%</td><td>43.5</td><td>-12%</td><td>99.7</td><td>89.9</td><td>11%</td><td>398.5</td><td>386.0</td><td>3%</td></t<>	HSD	38.2	61.4	-38%	43.5	-12%	99.7	89.9	11%	398.5	386.0	3%
Total 101.9 131.6 -23% 112.9 -10% 233.5 266.0 -12% 928.7 1,044.7 -11% HASCOL MS 23.9 25.9 -8% 16.7 43% 49.8 32.1 55% 199.4 170.3 17% HSD 16.1 22.3 -28% 10.1 60% 38.4 17.7 118% 129.6 82.3 58% FO - 0 - 0% - 0% - 0% - 0% - 0% - 0% - 0%	FO	10.8	10.8	0%	12.1	-11%	21.6	58.3	-63%	78.3	200.7	-61%
HASCOL MS 23.9 25.9 -8% 16.7 43% 49.8 32.1 55% 199.4 170.3 17% HSD 16.1 22.3 -28% 10.1 60% 38.4 17.7 118% 129.6 82.3 58% FO 0% - 0% 0% - 0% 0% - 0% -	Others	5.8	5.6	4%	2.7	115%	11.4	5.8	97%	37.2	25.0	49%
MS 23.9 25.9 -8% 16.7 43% 49.8 32.1 55% 199.4 170.3 17% HSD 16.1 22.3 -28% 10.1 60% 38.4 17.7 118% 129.6 82.3 58% FO 0% - 0% - 0% - 0% 0% - 0% Others 2.6 2.5 5% 0.1 2815% 5.1 0.1 5590% 9.7 0.4 2476% Fotal 42.6 50.7 -16% 26.8 59% 93.3 49.8 87% 338.8 252.9 34% SHEL MS 50.9 59.1 -14% 55.7 -9% 110.0 118.6 -7% 462.3 456.8 1% HSD 26.1 35.9 -27% 31.9 -18% 61.9 65.3 -5% 262.6 261.1 1% FO 0% 0% - 0% - 0% - 0% - 0% - 0%	Total	101.9	131.6	-23%	112.9	-10%	233.5	266.0	-12%	928.7	1,044.7	-11%
HSD 16.1 22.3 -28% 10.1 60% 38.4 17.7 118% 129.6 82.3 58% FO - 0 0% - 0% - 0% - 0% - 0% - 0% - 0% -	HASCOL											
FO 0% - 0% - 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% - 0.4 2476% 0% - 0.4 2476% 0%	MS	23.9	25.9	-8%	16.7	43%	49.8	32.1	55%	199.4	170.3	17%
FO 0% - 0% - 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% - 0.4 2476% 0 0% - 0.4 2476% 0 0% - 0.4 2476% 0 0% - 0.4 2476% 0 0% - 0	HSD	16.1	22.3	-28%	10.1	60%	38.4	17.7	118%	129.6	82.3	58%
Fotal 42.6 50.7 -16% 26.8 59% 93.3 49.8 87% 338.8 252.9 34% SHEL MS 50.9 59.1 -14% 55.7 -9% 110.0 118.6 -7% 462.3 456.8 1% HSD 26.1 35.9 -27% 31.9 -18% 61.9 65.3 -5% 262.6 261.1 1% FO - - 0% - - 0% - - 0% Others 6.9 6.4 8% 1.9 265% 13.3 3.5 282% 37.3 14.1 164% Total 83.8 101.4 -17% 89.4 -6% 185.2 187.4 -1% 762.2 732.0 4%	FO	-		0%	-	0%	-	-	0%	-	-	0%
SHEL MS 50.9 59.1 -14% 55.7 -9% 110.0 118.6 -7% 462.3 456.8 1% HSD 26.1 35.9 -27% 31.9 -18% 61.9 65.3 -5% 262.6 261.1 1% FO - - 0% - - 0% - - 0% Others 6.9 6.4 8% 1.9 265% 13.3 3.5 282% 37.3 14.1 164% Total 83.8 101.4 -17% 89.4 -6% 185.2 187.4 -1% 762.2 732.0 4%	Others	2.6	2.5	5%	0.1	2815%	5.1	0.1	5590%	9.7	0.4	2476%
MS 50.9 59.1 -14% 55.7 -9% 110.0 118.6 -7% 462.3 456.8 1% HSD 26.1 35.9 -27% 31.9 -18% 61.9 65.3 -5% 262.6 261.1 1% FO 0% - n/m 0% 0% Others 6.9 6.4 8% 1.9 265% 13.3 3.5 282% 37.3 14.1 164% Fotal 83.8 101.4 -17% 89.4 -6% 185.2 187.4 -1% 762.2 732.0 4%	Total	42.6	50.7	-16%	26.8	59%	93.3	49.8	87%	338.8	252.9	34%
MS 50.9 59.1 -14% 55.7 -9% 110.0 118.6 -7% 462.3 456.8 1% HSD 26.1 35.9 -27% 31.9 -18% 61.9 65.3 -5% 262.6 261.1 1% FO 0% - n/m 0% 0% Others 6.9 6.4 8% 1.9 265% 13.3 3.5 282% 37.3 14.1 164% Fotal 83.8 101.4 -17% 89.4 -6% 185.2 187.4 -1% 762.2 732.0 4%	SHEL											
HSD 26.1 35.9 -27% 31.9 -18% 61.9 65.3 -5% 262.6 261.1 1% FO - 0% - n/m 0% - 0% Others 6.9 6.4 8% 1.9 265% 13.3 3.5 282% 37.3 14.1 164% Fotal 83.8 101.4 -17% 89.4 -6% 185.2 187.4 -1% 762.2 732.0 4%	MS	50.9	59.1	-14%	55.7	-9%	110.0	118.6	-7%	462.3	456.8	1%
FO 0% - n/m 0% 0% Others 6.9 6.4 8% 1.9 265% 13.3 3.5 282% 37.3 14.1 164% Fotal 83.8 101.4 -17% 89.4 -6% 185.2 187.4 -1% 762.2 732.0 4%	HSD											
Others 6.9 6.4 8% 1.9 265% 13.3 3.5 282% 37.3 14.1 164% Fotal 83.8 101.4 -17% 89.4 -6% 185.2 187.4 -1% 762.2 732.0 4%	FO							-				
Total 83.8 101.4 -17% 89.4 -6% 185.2 187.4 -1% 762.2 732.0 4%	Others	6.9	6.4		1.9		13.3	3.5		37.3	14.1	
	Total											



Important Disclaimer and Disclosures

Research Analyst(s) Certification: The Research Analyst(s) hereby certify that the views about the company/companies and the security/ securities discussed in this report accurately reflect his or her or their personal views and that he/she has not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report. The analyst(s) is principally responsible for the preparation of this research report and that he/she or his/her close family/relative does not own 1% or more of a class of common equity securities of the following company/companies covered in this report.

Disclaimer: The information and opinions contained herein are prepared by IGI Finex Securities Limited and is for information purposes only. Whilst every effort has been made to ensure that all the information (including any recommendations or opinions expressed) contained in this document (the information) is not misleading or unreliable, IGI Finex Securities Limited makes no representation as to the accuracy or completeness of the information. Neither, IGI Finex Securities Limited nor any director, officer or employee of IGI Finex Securities Limited shall in any manner be liable or responsible for any loss that may be occasioned as consequence of a party relying on the information. This document takes no account of the investment objectives, financial situation and particular needs of investors, who shall seek further professional advice before making any investment decision. The subject Company (ies) is a client of the IGI Finex Securities Limited and IGI Finex Securities offers brokerage services to Subject Company (ies) on a regular basis, in line with industry practice. This document and the information may not be reproduced, distributed or published by any recipient for any purpose. This report is not directed or intended for distribution to, or use by any person or entity not a client of IGI Finex Securities Limited, else directed for distribution.

Rating system: IGI Finex Securities employs three tier ratings system, depending upon expected total return (return is defined as capital gain exclusive of tax) of the security in stated time period, as follows:

Recommendation Rating System

Buy if target price on aforementioned security (ies) is more than 10%, from its last closing price(s)
Hold if target price on aforementioned security (ies) is in between -10% and 10%, from its last closing price(s)
Sell if target price on aforementioned security (ies) is less than -10%, from its last closing price(s)

Valuation Methodology: To arrive at Target Prices, IGI Finex Securities uses different valuation methodologies including

- Discounted Cash Flow (DCF)
- Reserve Based DCF
- Dividend Discount Model (DDM)
- Justified Price to Book
- Residual Income (RI)
- Relative Valuation (Price to Earning, Price to Sales, Price to Book)

Risk: Investment in securities are subject to economic risk, market risk, interest rate risks, currency risks, and credit risks, political and geopolitical risks. The performance of company (ies) covered herein might unfavorably be affected by multiple factors including, business, economic, and political conditions. Hence, there is no assurance or guarantee that estimates, recommendation, opinion, etc. given about the security (ies)/company (ies) in the report will be achieved.

Basic Definitions and Terminologies used: Target Price: A price target is the projected price level of a financial security stated by an investment analyst or advisor. It represents a security's price that, if achieved, results in a trader recognizing the best possible outcome for his investment, Last Closing: Latest closing price, Market Cap.: Market capitalization is calculated by multiplying a company's shares outstanding by current trading price. EPS: Earnings per Share. DPS: Dividend per Share. ROE: Return on equity is the amount of net income returned as a percentage of shareholders' equity. P/E: Price to Earnings ratio of a company's share price to its per-share earnings. P/B: Price to Book ratio used to compare a stock's market value to its book value. DY: The dividend yield is dividend per share, divided by the price per share.

IGI Finex Securities Limited
Research Analyst(s)
Research Identity Number: R

Research Identity Number: BRP009

© Copyright 2024 IGI Finex Securities Limited



Contact Details

Equity Sales

Zaeem Haider Khan	Head of Equities	Tel: (+92-42) 35301405	zaeem.haider@igi.com.pk
Muhammad Naveed	Regional Manager (Islamabad & Upper North)	Tel: (+92-51) 2604861-62	muhammad.naveed@igi.com.pk
Syeda Mahrukh Hameed	Branch Manager (Lahore)	Tel: (+92-42) 38303564	mahrukh.hameed@igi.com.pk
Shakeel Ahmad	Branch Manager (Faisalabad)	Tel: (+92-41) 2540843-45	shakeel.ahmad1@igi.com.pk
Asif Saleem	Equity Sales (RY Khan)	Tel: (+92-68) 5871652-56	asif.saleem@igi.com.pk
Mehtab Ali	Equity Sales (Multan)	Tel: (+92-61) 4512003	mahtab.ali@igi.com.pk

Research Team

Abdullah Farhan	Head of Research	Tel: (+92-21) 111-234-234 Ext: 912	abdullah.farhan@igi.com.pk
Sakina Makati	Research Analyst	Tel: (+92-21) 111-234-234 Ext: 810	sakina.makati@igi.com.pk
Laraib Nisar	Research Analyst	Tel: (+92-21) 111-234-234 Ext: 974	laraib.nisar@igi.com.pk

IGI Finex Securities Limited

Trading Rights Entitlement Certificate (TREC) Holder of Pakistan Stock Exchange Limited | Corporate member of Pakistan Mercantile Exchange Limited Website: www.igisecurities.com.pk

Head Office

Suite No 701-713, 7th Floor, The Forum, G-20, Khayaban-e-Jami Block-09, Clifton, Karachi-75600 UAN: (+92-21) 111-444-001 | (+92-21) 111-234-234 Fax: (+92-21) 35309169, 35301780

Lahore Office	Islamabad Office
Shop # G-009, Ground Floor,	3 rd Floor, Kamran Centre,
Packages Mall	Block- B, Jinnah Avenue, Blue Area
Tel: (+92-42) 38303560-69	Tel: (+92-51) 2604861-2, 2604864, 2273439
Fax: (+92-42) 38303559	Fax: (+92-51) 2273861
Faisalabad Office	Rahim Yar Khan Office
Office No. 2, 5 & 8, Ground Floor, The	Plot # 12, Basement of Khalid Market,
Regency International 949, The Mall	Model Town, Town Hall Road
Faisalabad	Tel: (+92-68) 5871652-3
Tel: (+92-41) 2540843-45	Fax: (+92-68) 5871651
Multan Office	
Mezzanine Floor, Abdali Tower,	
Abdali Road	
Tel: (92-61) 4512003, 4571183	

IGI Finex Securities Limited Research Analyst(s)

Research Identity Number: BRP009

© Copyright 2024 IGI Finex Securities Limited